Related Experiment Videos
Novel agents for managing dyslipidaemia
1University of Melbourne, Department of Medicine, St Vincent's Hospital Melbourne, Victoria 3065, Australia. jdbest@unimelb.edu.au
Insights
Lowering low-density lipoprotein (LDL) cholesterol with statins reduces coronary heart disease (CHD) risk. Future treatments aim to address all lipid abnormalities, including low high-density lipoprotein (HDL) cholesterol, for comprehensive CHD prevention.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Metabolic Disorders
Background:
- Elevated low-density lipoprotein (LDL) cholesterol is a significant predictor of coronary heart disease (CHD).
- Statins (HMG-CoA reductase inhibitors) are widely used for primary and secondary prevention of CHD by lowering LDL cholesterol.
- Treatment challenges persist regarding optimal LDL reduction and combination therapies for very high LDL levels.
Purpose of the Study:
- To review current treatment issues and novel agent development for lipid management in CHD prevention.
- To focus on patients with low high-density lipoprotein (HDL) cholesterol, often associated with hypertriglyceridaemia and insulin resistance.
- To explore future strategies for comprehensive lipid abnormality correction beyond LDL lowering.
Main Methods:
- Review of accumulated evidence on statin efficacy and treatment challenges.
- Discussion of emerging therapeutic targets and drug classes for lipid modification.
- Analysis of the link between metabolic syndrome components (insulin resistance, obesity, diabetes) and dyslipidaemia.
Main Results:
- Statins effectively reduce CHD risk by lowering LDL cholesterol.
- Novel agents are being developed to target low HDL cholesterol, including CETP inhibitors, RXR agonists, PPAR agonists, and estrogen-like compounds.
- Agents targeting both cholesterol and triglycerides, such as MTP inhibitors and AMP kinase agonists, are under investigation.
Conclusions:
- Future CHD prevention strategies will emphasize correcting all lipid abnormalities, not solely focusing on LDL cholesterol reduction.
- Addressing low HDL cholesterol and hypertriglyceridaemia is crucial, especially with rising rates of obesity, diabetes, and insulin resistance.
- Combination therapies and novel agents offer promising avenues for comprehensive lipid management and cardiovascular risk reduction.
Abstract:
An elevated low-density lipoprotein (LDL) cholesterol level is a strong predictor of coronary heart disease (CHD) risk. Over the past seven years, equally strong evidence has accumulated that lowering LDL cholesterol with HMG-CoA reductase inhibitors or statins reduces CHD risk and there is now widespread use of these agents for the primary and secondary prevention of CHD. Treatment issues remain regarding the appropriate degree of LDL cholesterol reduction and whether, in people with very high levels, it would be preferable to achieve the LDL cholesterol goal with a powerful statin alone or combined with an agent that lowers LDL cholesterol by a different mechanism. The main focus in the development of novel agents is the patient with low high-density lipoprotein (HDL) cholesterol, usually associated with hypertriglyceridaemia. Already prevalent as a risk factor for CHD, this abnormality has been linked with insulin resistance, which is likely to increase greatly over the next decade, along with increasing obesity and diabetes. Agents that have potent HDL cholesterol raising capacity include cholesteryl ester transfer protein (CETP) inhibitors, retinoid X receptor (RXR) selective agonists, specific peroxisome proliferator-activated receptor (PPAR) agonists and oestrogen-like compounds. Another area of development involves agents that will lower both cholesterol and triglyceride levels, such as partial inhibitors of microsomal triglyceride transfer protein (MTP) and perhaps squalene synthase inhibitors and agonists of AMP kinase. Future emphasis will be on correcting all lipid abnormalities for the prevention of CHD, not just lowering LDL cholesterol.